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Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-eﬀ ective directly 
observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium 
tuberculosis were susceptible to ﬁ rst-line tuberculosis drugs, and drug resistance was not a major issue. However, in 
2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) 
tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in 
the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) 
tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable 
tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis 
pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of 
drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the 
epidemic; and suggest speciﬁ c recommendations for important next steps. Visionary political leadership is needed 
to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of 
global and regional action plans.
Introduction
Tuberculosis is a leading cause of death by an infectious 
disease worldwide, despite global eﬀ orts and ﬁ nancial 
investment by governments and non-govern mental 
organisations in disease-control pro grammes during 
the past 20 years.1 In its 2012 global report on 
tuberculosis,2 WHO estimates that 3·7% (range 
2·1–5·2%) of new cases and 20% (range 13–26%) of 
pre viously treated cases have multidrug-resistant 
(MDR) tuberculosis (deﬁ ned as tuberculosis caused by 
Mycobacterium tuberculosis isolates that are resistant to 
rifampicin and isoniazid). In many countries in eastern 
Europe and central Asia, 9–32% of new patients and 
more than 50% of previously treated patients have 
MDR tuberculosis.2 After initial reports in 2006 from 
South Africa of extensively drug-resistant (XDR) 
tuberculosis (deﬁ ned as tuber culosis caused by strains 
of M tuberculosis resistant to rifampicin, isoniazid, 
ﬂ uoroquinolones, and any of the second-line injec-
table drugs such as capreomycin, amikacin, and 
kanamycin),3,4 the number of countries reporting cases 
of XDR tuberculosis has increased: 84 countries 
reported at least one case at the last count in 2011 
(ﬁ gure 1). Eastern European countries have the highest 
rates of drug-resistant tuberculosis worldwide, and 
most cases of MDR tuberculosis arise in populous 
Asian countries such as China, India, the Philippines, 
and Indonesia. 
Although large gaps in our knowledge of the occurrence 
of MDR and XDR tuberculosis remain, much progress is 
being made in estimation of the burden of drug resistance 
through surveys and roll-out of rapid diagnostics in some 
countries. In 2011, nearly 60 000 cases of MDR tuber-
culosis were detected, treated, and notiﬁ ed.2 Inappropriate 
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Key messages
• For many decades, the response to global tuberculosis by 
governments in both wealthy and disease-endemic 
countries has been complacent and politically neglectful
• Rising rates of multidrug-resistant and extensively 
drug-resistant tuberculosis threaten global control eﬀ orts 
in both developing and developed countries
• The development of new rapid diagnostics and tuberculosis 
drug pipelines need to be maintained and strengthened
• Rapid and accurate diagnosis of drug-resistant tuberculosis 
needs to be scaled up worldwide, and robust treatment 
programmes with quality assured drugs and patient 
support programmes should be provided
• The serious threat posed by drug-resistant tuberculosis 
needs to be acknowledged worldwide, before it rises to 
rates that overwhelm the health systems, as seen in several 
countries of the former Soviet Union
• Strong political commitment and adequate funding should 
underpin the implementation of a global strategy to tackle 
the wider societal and health-service determinants of 
multidrug-resistant and extensively drug resistant 
tuberculosis
• A major conceptual change and visionary global leadership 
are needed to move away from the conventional view that 
tuberculosis is only a disease of poor nations
530 www.thelancet.com/infection   Vol 13   June 2013
Series
Research and Training Project, 
University Teaching Hospital, 
Lusaka, Zambia (P Mwaba FRCP, 
Adam Zumla MD , M Bates); 
Ministry of Health, Lusaka, 
Zambia (P Mwaba); 
Department of Respiratory 
Medicine, Royal Free Hospital 
NHS Foundation Trust, 
University College London, 
London, UK (M Lipman FRCP); 
University of Zimbabwe, 
College of Health Sciences, 
Harare, Zimbabwe 
(Prof L Zijenah PhD); School of 
Pharmacy, London, UK 
(Adam Zumla); India 800 
Foundation, New Delhi, India 
(K Sarda MD); Division of 
Pulmonary and Critical Care, 
University of California, 
San Francisco, CA, USA 
(P Nahid MD); Department for 
Infectious Diseases and Tropical 
Medicine, Klinikum of the 
University of Munich, Munich, 
Germany 
(Prof M Hoelscher FRCP); 
Institute of Medical 
Microbiology, University of 
Zurich, Zurich, Switzerland 
(M Pletschette FRCP); WHO 
Collaborating Centre for TB and 
Lung Diseases, Fondazione S 
Maugeri, Care and Research 
Institute, Tradate, Italy 
(Prof G B Migliori FRCP); 
Ministry of Health, Riyadh, 
Saudi Arabia 
(Prof Z A Memish FRCP); College 
of Medicine, Alfaisal University, 
Riyadh, Saudi Arabia 
(Z A Memish); Global Health 
Institute, École Polytechnique 
Fédérale de Lausanne, 
Lausanne, Switzerland 
(Prof S Cole PhD); Department 
of Microbiology, Karolinska 
Institute, Stockholm, Sweden 
(Prof M Maeurer FRCP); 
Henry M Jackson 
Foundation-Division of AIDS, 
National Institute of Allergy 
and Infectious Diseases, 
National Institutes of Health, 
Bethesda, MD, USA 
(M Schito PhD); and Division of 
AIDS, National Institute of 
Allergy and Infectious Diseases, 
National Institutes of Health, 
Bethesda, MD, USA (P Kim MD, 
R Hafner MD) 
Correspondence to: 
Prof Alimuddin Zumla, Centre for 
Clinical Microbiology, 
Department of Infection, 
University College London Royal 
Free Campus, Royal Free 
Hospital, London NW3 2PF, UK 
a.zumla@ucl.ac.uk 
monotherapy and intermittent treatment are the main 
causes of drug resistance, and facilitate the selection and 
transmission of resistant strains of M tuberculosis within 
communities. Once MDR and XDR tuberculosis emerge 
in a population, several social, health service, manage-
ment, and control issues help to transmit the disease 
within communities, health-care establishments, and 
congregate settings such as prisons and mines.
The widespread emergence of XDR tuberculosis could 
lead to virtually untreatable tuberculosis. With ease of 
international travel, and increased rates of MDR tuber-
culosis in eastern Europe, central Asia, and elsewhere, the 
threat and range of the spread of untreatable tuberculosis 
is very real.5,6 Calls in 2012 to bring back sanatoria, indicate 
the desperate situation as perceived by practising 
physicians in Africa and Europe.7 We provide an overview 
of the global burden of drug-resistant tuberculosis, and 
discuss the social, political, health service, management, 
and control issues that fuel trans mission worldwide. We 
detail speciﬁ c recom mendations for the next steps needed 
to inform policy, establish research priorities, and ensure 
the best returns for investment in control of the disease.
The global burden of drug-resistant tuberculosis 
In 2011, WHO estimated 12 million prevalent cases of 
tuberculosis worldwide,2 of which about 630 000 (roughly 
5%) were MDR tuberculosis (ﬁ gure 2). Drug-resistance 
caused by primary transmission is a growing concern.8 The 
frequency of MDR tuberculosis varies greatly between 
countries. In most resource-limited countries, data for drug 
resistance are collected through surveys of a representative 
sample of patients with the disease (table). Although nearly 
all countries with a high burden of tuberculosis and drug-
resistant tuberculosis have information about prevalence of 
resistance to ﬁ rst-line drugs, this information might be old 
or not nationally representative. Unfortunately, because of 
insuﬃ  cient diagnostic facilities, the number of MDR 
tuberculosis cases reported in 2011 represents only 19% of 
the estimated 440 000 cases of MDR tuberculosis in patients 
with pulmonary tuberculosis, and less than 10% in the two 
countries with the largest number of cases (China and 
India).9
In 2011, ﬁ rst-line drug-sensitivity testing was done in 
only a few patients worldwide: less than 4% of new 
bacteriologically conﬁ rmed cases and 6% of previously 
treated cases.2 Data on the magnitude of drug resistance 
in children are scarce.10 WHO estimates of MDR 
tuberculosis notiﬁ cation are made on the basis of either 
routine surveillance (for the few countries with data), or 
are modelled with data from countries that are regarded 
as similar.2 The highest caseloads of MDR tuberculosis 
are reported in India, China, Russia, and South Africa, 
accounting for more than 60% of cases worldwide.11 In 
2007, a national survey estimating the incidence of drug-
resistant tuberculosis in China showed that the country 
has a serious epidemic of drug-resistance, with one in 
ten patients estimated to have MDR tuberculosis.8 In 
several eastern European and central Asian countries, 
such as Belarus, Kazakhstan, and regions of Russia such 
as Arkhangelsk Oblast, more than 30% of newly 
diagnosed patients with tuberculosis have MDR 
tuberculosis, suggesting the success ful transmission of 
At least one case reported
No cases reported
Not applicable
Figure 1: Countries with at least one case of extensively drug-resistant tuberculosis by the end of 2011
Reproduced from WHO’s global tuberculosis report 2012,2 by permission of the World Health Organization.
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drug-resistant M tuberculosis strains.11 The levels of MDR 
tuberculosis are highest in previously treated cases 
(ﬁ gure 3). Aside from MDR tuberculosis, the most severe 
drug resistance arises in eastern Europe and central Asia. 
Worldwide, 9% (95% CI 6·7–11·2) of patients with MDR 
tuberculosis have XDR tuberculosis, and 14·5% 
(11·6–17·4) have additional resistance to a ﬂ uoro-
quinolone—ie, pre-XDR tuberculosis. XDR and pre-XDR 
tuberculosis are underdetected in many countries.2
Although China and India are large emerging 
economies that have the resources to substantially reduce 
the prevalence of MDR tuberculosis, these countries have 
the highest number of MDR tuberculosis cases 
worldwide.2 In 2000, the Chinese Government started to 
revitalise its tuberculosis programme; its acceptance of 
tuberculosis as a major health issue, and the subsequent 
strong political commitment have led to major successes 
in control of the disease.12 In India’s private sector, the 
national surveillance programme does not detect 
tuberculosis in many patients,12 and the quality of 
diagnostic and treatment services by family doctors is a 
major issue. In December, 2012, doctors from Mumbai 
reported cases of totally drug–resistant tuberculosis 
(TDR),13 which generated major political interest and 
concern. However, use of the term TDR is controversial 
since no reliable deﬁ nition beyond XDR tuberculosis is 
practicable.14–16 Tuberculosis has now been made a 
notiﬁ able disease in India, laboratory and curative services 
have been strengthened, and eﬀ orts to increase private-
sector participation in tuberculosis control have been 
stepped up.17 A national drug resistance survey to measure 
the magnitude of drug-resistant tuberculosis in India has 
never been undertaken, although there are plans to 
conduct such a survey in 2013. Surveys in Andhra Pradesh, 
Gujarat, and Tamil Nadu states showed that up to 3% of 
new cases, and 13–17% of previously treated cases, were of 
MDR tuberculosis.17 The ﬁ rst national survey of drug-
resistance to measure the magnitude of drug-resistant 
tuberculosis across India is planned for this year. 
15 of the 27 countries with the highest burden of MDR 
tuberculosis are in the WHO European region.2 More 
than 80 000 cases of MDR tuberculosis occur in the 
region each year—almost a ﬁ fth of the world’s total MDR 
tuberculosis burden.18 The ﬁ ndings of a 2012 study 
showed that in Minsk, Belarus, almost 50% of reported 
tuberculosis cases, and 75·76% of previously treated 
cases in 2011, were multidrug resistant.19 Precise data for 
MDR and XDR tuberculosis in Europe are not available 
because most eastern European countries have poor 
diagnostic services and suboptimum surveillance 
systems to detect drug-resistant tuberculosis.20
Global implications of the rising MDR 
tuberculosis levels in high-incidence countries
These developments are of importance outside the 
borders of high-incidence countries. Many countries 
with low incidence of tuberculosis, including western 
Europe and the USA, receive millions of travellers from 
India, Europe, Africa, and China. Many travellers settle 
in the countries they move to, but maintain regular 
Percentage of cases
 0–2·9
 3·0–5·9
 6·0–11·9
 12·0–17·9
 ≥18
 No data
 Subnational data only
 Not applicable
Figure 2: Percentage of new tuberculosis cases with multidrug-resistant tuberculosis
Based on the most recent year for which data have been reported, which varies among countries. Reproduced from WHO’s global tuberculosis report 2012,2 by 
permission of the World Health Organization.
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contact with their country of origin. In the UK, 
particularly London, the rates of tuberculosis have risen 
over the past 20 years,21 especially in deprived groups.22 
The 2012 UK annual tuberculosis report23 showed that 
the number of cases resistant to any ﬁ rst-line drug rose 
from 206 (6·4%) in 2000, to 431 (8·4%) in 2011.23 The 
number of cases of MDR tuberculosis increased from 
28 in 2000, to 81 in 2011; in 2011 alone, the number 
increased by 26%. Most cases of MDR tuberculosis are in 
patients born outside the UK, which suggests importation 
from abroad including eastern Europe, sub-Saharan 
Africa,24 and the Indian subcontinent.23 However, in 
London, isoniazid resistance is more common in UK-
born patients than in non-UK-born patients because of 
an outbreak that has continued for more than a decade.25 
Cases of XDR tuberculosis pose challenges to clinical 
services.26,27 Since 1995, 24 cases of XDR tuberculosis 
have been reported. The highest number of cases (six) 
was reported in 2011.
Although several countries with a low incidence of 
tuberculosis use pre-entry screening of immigrants to 
detect the disease,27,28 these programmes focus on the 
identiﬁ cation of active tuberculosis cases. Even with entry 
measures to detect and treat latent tuberculosis infection, 
present prophylactic treatment with isoniazid or 
rifampicin, or both, would likely be useless in most 
individuals infected with strains of MDR tuberculosis. 
This issue should be addressed in the country of origin, 
and high-burden countries should be supported in their 
eﬀ ort to control drug-resistant tuberculosis. As the global 
economic inﬂ uence of China and India expands, these 
countries should contribute to drug-resistant tuberculosis 
control in poorer countries.
Social, health service, management, and 
control issues 
Factors driving drug-resistant tuberculosis
MDR and XDR tuberculosis arise because of inadequate 
or interrupted administration of ﬁ rst-line treatment.29–31 
If patients are given too few drugs, for too short a period, 
or given drugs to which infecting strains are partly drug 
resistant, the resistant strains are favoured and will 
eventually predominate in the body.32 However, once 
drug-resistant strains of M tuberculosis have been 
selected and occur in a community, they are directly 
transmitted to others. Many factors then propagate the 
spread of drug-resistant tuberculosis, and lead to 
widespread emergence of XDR tuberculosis. These 
factors include: lack of rapid, cheap, and accessible 
point-of-care diagnostic methods to rapidly diagnose 
drug-resistant tuberculosis as early as possible;33 
insuﬃ  cient second-line drug options; poor patient 
adherence to prolonged treatment; inadequate case 
holding; poor treatment strategies;31 social stigma; 
deprivation and poverty; absence of community 
engagement; insuﬃ  cient political will; and inadequate 
resources.34 The complex interaction between the host 
and M tuberculosis, aﬀ ected by concomitant infections35 
and wider social determinants, compound these 
structural factors. The genetic makeup of some 
M tuberculosis strains could increase risk of drug 
resistance.36,37 In several countries, primary transmission 
of MDR and XDR tuberculosis have been well 
documented,38–42 and have drawn attention to the crucial 
need to implement infection control precautions in 
congregate settings.40,43
Total conﬁ rmed 
cases of MDR 
tuberculosis*
Estimated cases of MDR 
tuberculosis among notiﬁ ed 
cases of tuberculosis
Worldwide
2005 11 988 ··
2009 46 897 ··
2010 54 987 ··
2011 61 690† 310 000 (220 000–400 000)
Africa
2005 2445 ..
2009 10 741 ..
2010 9340 ..
2011 12 384 45 000 (7900–82 000)
The Americas 
2005 4427 ..
2009 2884 ..
2010 2661 ..
2011 3474 5900 (3400–8400)
Eastern Mediterranean
2005 350 ..
2009 496 ..
2010 886 ..
2011 841 17 000 (0–38 000)
Europe
2005 4347 ..
2009 28 157 ..
2010 33 863 ..
2011 33 984 76 000 (64 000–87 000)
Southeast Asia
2005 68 ..
2009 2560 ..
2010 3942 ..
2011 6615 89 000 (76 000–100 000)
Western Paciﬁ c
2005 351 ..
2009 2059 ..
2010 4295 ..
2011 4392 78 000 (60 000–95 000)
Data in parantheses are the range. MDR=multidrug resistant.*Includes cases with 
unknown previous treatment history. †Total number reported to have started 
appropriate treatment is 55 597 (<20% of all estimated MDR tuberculosis cases; 
treatment success rates for programmatic management of MDR tuberculosis are 
in the order of 50%). Data taken from reference 2.
Table: Global estimates of multidrug-resistant tuberculosis by world 
region, 2005–11
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Diagnostic and treatment challenges
The prevalence of MDR and XDR tuberculosis and the 
size of the recent increase are likely to be underestimated 
because of insuﬃ  cient laboratory facilities for drug 
susceptibility testing in most countries with high 
tuberculosis burden. Unfortunately, most laboratories 
are ill equipped to detect and diagnose the extent of drug 
resistance, which represents a major bottleneck for 
continuous surveillance of drug-resistant tuberculosis 
based on routine drug-sensitivity testing of all micro-
biologically conﬁ rmed cases. Because most national 
programmes fail to diagnose and treat MDR and XDR 
tuberculosis, reported data are often unrepresentative; 
only 65 countries and three territories are deemed to 
report representative and good quality data.2
Diagnostic constraints are the ﬁ rst barrier to treatment; 
therefore, eﬀ orts to scale up the availability of drug-
sensitivity testing should be the ﬁ rst step to improve 
treatment. The second barrier is the access to a quality 
assured treatment programme once the diagnosis has 
been established. In most high-burden settings, 
treatment programmes for drug-resistant tuberculosis 
are insuﬃ  cient. Several countries have developed plans 
for the up-scaling of treatment programmes for MDR 
tuberculosis; however, these plans rely on international 
donor funding, have been negatively aﬀ ected by the 
funding shortfall at the Global Fund,44 and are not 
sustainable in the long term at present funding amounts. 
To contain the spread of drug-resistant tuberculosis 
would need a consistent supply of second-line drugs 
supported by adequate resources to ensure treatment 
uptake, prevention, management of adverse eﬀ ects, and 
halting of transmission worldwide. The Global Plan to 
Stop TB 2011–15 set a target to successfully treat more 
than 75% of MDR tuberculosis cases by 2015. 
Unfortunately, only 30 of the 107 countries that reported 
outcome data for MDR tuberculosis treatment for 2011 
reached this goal.2 The universal availability of drug-
sensitivity testing and scaling up of MDR tuberculosis 
treatment and control programmes need serious 
political commitment from national and international 
leaders, continued innovation, and implementation of 
bold and pragmatic approaches. 
Management of children
Epidemiologically, MDR tuberculosis in children is 
particularly important because tuberculosis in children is 
usually acquired because of recent exposure, suggesting 
continuing community transmission. Findings from 
several case series have shown that children are likely to 
develop MDR and XDR tuberculosis in settings where 
transmission is poorly controlled.45 These children are at 
an additional dis advantage because bacteriological 
sampling to diagnose drug-resistance is diﬃ  cult. The pill 
burden is huge, and age-appropriate paediatric 
formulations are unavailable for most second-line drugs.46 
Adverse eﬀ ects, especially hearing loss induced by 
injectable agents, are a major concern in young and 
developing children (<16 years of age).47 However, excellent 
outcomes can be achieved, with generally better treatment 
Percentage of cases
 0–5·9
 6·0–11·9
 12·0–29·9
 30·0–49·9
 ≥50
 No data
 Subnational data only
 Not applicable
Figure 3: Percentage of previously treated tuberculosis cases with multidrug-resistant tuberculosis
*Based on the most recent year for which data have been reported, which varies among countries. Reproduced from WHO’s global tuberculosis report 2012,2 by 
permission of the World Health Organization.
For the WHO Global Plan to 
Stop TB 2011–15 see http://
www.stoptb.org/global/plan/
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outcomes than those achieved in adults.48 Unfortunately, 
access to treatment is severely restricted, and few MDR 
treatment programmes oﬀ er treatment to young children. 
Inadequate infection control 
Insuﬃ  cient infection control is a major cause of 
transmission of drug-resistant tuberculosis49,50—eg, the 
2006 XDR tuberculosis outbreak in a high-HIV 
prevalence setting in Kwazulu Natal, South Africa, where 
infection control practices vary widely.40,51 Attempts to 
control MDR tuberculosis worldwide need to include 
robust infection control measures in all health-care 
settings through containment of aerosol transmission. 
At a community level, the most eﬀ ective strategy is early 
diagnosis and prompt initiation of appropriate treatment, 
although creative strategies to reduce transmission 
within identiﬁ ed transmission hotspots should be 
considered in high-burden communities.
Social and health service determinants
Health system failures generally underpin the emergence 
of drug resistance in a population. Factors such as poor 
diagnostic facilities, insuﬃ  cient regulation of access to 
antibiotics, poor implementation of the directly observed 
treatment short-course programme, and lack of tuber-
culosis drugs lead to monotherapy and intermittent 
treatment. Factors related to society and health services 
that underlie the epidemic diﬀ er by region—eg, in Russia, 
high rates of tuberculosis in prisons with poor quality 
management contributed to the emergence of MDR 
transmission, with subsequent spread into the 
community.52 In India, huge variations in the quality of 
management practices in public-sector and private-sector 
facilities probably play a major part in the emergence of 
drug-resistant tuberculosis.53 Transmission, including 
nosocomial spread, has contributed to the rise in drug-
resistant tuberculosis in China8 and South Africa.51 By 
contrast, properly resourced and organised health systems 
are less likely to generate drug-resistant tuberculosis, as 
shown by the low rates of MDR tuberculosis in patients in 
western Europe and North America.54,55 The highest 
burden of drug resistance arises in countries that can 
aﬀ ord ﬁ rst-line drugs, but have weak health-care systems 
that are likely to generate MDR and XDR tuberculosis.2 
This situation explains the relative over-representation in 
Brazil, Russia, India, China, and the emerging economies 
in the Asia-Paciﬁ c region.
Once drug resistance emerges, its subsequent trans-
mission is facilitated by a complex interplay of several 
factors. Individuals living in poverty in overcrowded 
conditions, homeless people, alcohol and drug users, 
incarcerated individuals, and other susceptible groups 
are more likely to sustain transmission.19,52,56 An additional 
factor is insuﬃ  cient community engagement in tuber-
culosis control.12 Countries with well run pro grammes 
supported by high-level political com mitment, early 
diagnosis, and access to quality assured drugs tend to 
have better treatment outcomes,57 although more 
operational data are needed to guide best practice.
In New York City, between 1979, and 1992, the number 
of patients with tuberculosis tripled, and the proportion 
of patients with MDR tuberculosis more than doubled.55,56 
Tuberculosis had resurfaced as a major public health 
problem because of reduced government funding of 
tuberculosis programmes and associated deterioration of 
tuberculosis  public health services, compounded by an 
increasing number of poor communities  and the advent 
of the HIV/AIDS epidemic. The detection of the large 
outbreak of MDR tuberculosis in New York City in the 
early 1990s, and MDR tuberculosis in prison guards, led 
to substantial political attention focused on tuberculosis 
resulting in resurgence of governmental ﬁ nancial and 
political commitment to the eradication of tuberculosis.58,59 
Nationwide, declining tuberculosis trends in the USA 
were reversed, and tuberculosis incidence increased by 
20% between 1985 and 1992. This reversal resulted in 
52 100 excess cases of tuberculosis during this time.60 
Subsequent political commitment and substantial 
investment have brought down tuberculosis rates in the 
USA to the lowest recorded so far.61 
However, outbreaks of the disease among disadvantaged 
people continue to challenge control eﬀ orts38,62—eg, the 
outbreak of tuberculosis at a homeless shelter in Illinois 
in January, 2010. Since September, 2011, 28 outbreak-
associated cases have been reported in shelter guests, 
suggesting continuing M tuberculosis transmission.63 
Unfortunately, outside the USA, western Europe, and 
Australia, major reservoirs of active tuberculosis exist. 
Since the 1980s, some European countries have also 
encountered a resurgence of tuberculosis21—eg among 
disadvantaged communities in the Netherlands. The 
Dutch Government pledged to control tuberculosis and 
drug-resistant tuberculosis with large ﬁ nancial invest-
ment into disease services. Tuberculosis control and 
surveillance is now an integral part of the health-care 
system in the Netherlands, and the country has one of the 
lowest tuberculosis rates in Europe.64
Although the rate of MDR tuberculosis is high in 
Estonia, the country has shown what is achievable with a 
coherent national programme underpinned by political 
will.65 The centralised national tuberculosis-control pro-
gramme supported speciﬁ c measures including targeting 
of inter ventions to susceptible groups such as alcoholics, 
drug users, and their families; minimisation of drug 
misuse by stopping sale of antituberculosis drugs in 
pharmacies; high-quality training for medical staﬀ ; and 
reliable supply of quality assured drugs. The replication of 
this model in other larger countries could decrease the 
current burden, but would need increased resources and 
commitment. A comparative study of WHO Green Light 
Committee programmes in ﬁ ve resource-poor settings, 
including Estonia, Latvia, Russia, and Peru, shows that 
cure rates in patients with MDR tuberculosis can be 
similar to those noted in richer countries.57 
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Limitations of MDR and XDR tuberculosis 
management
Although 310 000 cases of MDR tuberculosis were 
estimated to occur in patients with pulmonary tuber-
culosis in 2011, only 55 597 patients (<20% of estimated 
cases) were started on second-line treatment.2 This 
massive treatment gap shows that not enough is being 
done to help individual patients, and to contain the 
spread of MDR tuberculosis. 
Regimens for treatment of MDR tuberculosis are very 
long (≥20 months), poorly tolerated, expensive, and 
substantially less eﬀ ective than ﬁ rst-line treatment of drug-
susceptible tuberculosis.66,67 WHO reports show that only 
48% of the more than 25 000 patients with MDR 
tuberculosis from 107 countries who started MDR 
tuberculosis treatment in 2009 completed their treatment 
successfully because of deaths (15%), treatment 
interruptions (14%), treatment failure (9%), and 
insuﬃ  cient data (14%).2 An individual meta-analysis of 
9153 patients with MDR tuberculosis from 32 observational 
cohorts reported similarly dismal ﬁ ndings (success 54%, 
default 23%, failure or relapse 8%, and death 15%).68 
Patients with strains of tuberculosis that had acquired 
additional resistance to second-line injectable drugs, to 
ﬂ uoroquinolones, or both (XDR tuberculosis)69 had poor 
outcomes, with treatment success rates of less than 
50%,70–73 which is similar to outcomes seen in the pre-
chemotherapy era. These poor outcomes show the 
exhaustion of treatment options in patients who often have 
longstanding disease—although many patients with XDR 
tuberculosis have no history of previous tuberculosis 
treatment, suggesting failures in infection control. 
Access to treatment is poor for drug-resistant 
tuberculosis;74 however, in some high-burden countries, 
treatment success rates have improved, and cure rates of 
more than 75% are achievable.75 A study by Van Deun and 
colleagues76 in 2010, showed excellent results in patients 
with MDR tuberculosis from Bangladesh who were treated 
for 9 months with gatiﬂ oxacin, clofazimine, ethambutol, 
and pyrazinamide throughout the treatment period, 
supplemented by protionamide, kanamycin, and high-
dose isoniazid during an intensive phase of a minimum of 
4 months. The STREAM trial is assessing this regimen. 
Improved use of existing drugs could provide opportunities 
to improve control programmes. 
New drug development and treatment 
regimen approaches
Several national and international partners—eg, the Global 
Alliance for TB Drug Development (TB Alliance), the US 
National Institutes of Health (NIH), the US Centers for 
Disease Control and Prevention (CDC), and the European 
and Developing Countries Clinical Trials Partnership 
(EDCTP)—have started animal and human studies to test 
the eﬃ  cacy of drug combinations rather than individual 
drugs. These studies aim to shorten the time taken to 
derive an entirely new treatment regimen for both 
drug-susceptible and drug-resistant tuberculosis.77 
However, this approach will probably take 8–10 years 
because of regulatory, study design, and research grant-
awarding processes. Eﬀ orts through the clinical trial plan 
funded by the NIH, and the PANACEA consortium 
funded by EDCTP with adaptive designs could make the 
process quicker. Although this work has tremendous long-
term value, it does little to address the immediate needs of 
drug-resistant patients who are underserved by present 
treatments. The recent US Food and Drug Administration 
accelerated approval of bedaquiline, the soon expected 
approval of delamanid by the European Medicines Agency, 
and the advanced development of drugs such as PA-824 
(TB Alliance) beg the question: how should we use these 
new drugs in the treatment of drug-resistant tuberculosis?78 
Clinical trials such as the MARVEL study (ACTG 5319) in 
development by the AIDS Clinical Trials Group in 
collaboration with the TB Alliance, will investigate 
treatment regimens that include both old and new drugs, 
and will provide answers within the next 3–4 years. The 
dual goals of developing completely new regimens and 
optimising existing or partly new regimens are not 
incompatible, and the poor treatment success and high 
mortality associated with drug-resistant tuberculosis 
treatment means that both approaches should be taken as 
a matter of urgency. 
The beneﬁ cial eﬀ ects of pharmaceutical companies and 
public–private partnerships providing drugs and access to 
drug information cannot be overstated and should be 
encouraged. The gap between clinical eﬃ  cacy and 
programme eﬀ ectiveness is well recognised,79 and is 
especially important for second-line drugs because of the 
speciﬁ c challenges associated with the delivery of complex 
combinations of drugs in a routine pro grammatic setting. 
Cross-resistance is more likely with repurposed drugs; 
however, drug resistance can occur when new 
antituberculosis agents, both novel compounds and 
repurposed drugs,  are introduced into new combination 
treatment regimens.  These are the ﬁ rst antibiotics that 
have been developed speciﬁ cally against tuberculosis in 
nearly half a century. Cross-resistance is also likely when 
drugs with other indications repurposed as anti tuber-
culosis agents such as linezolid, meropenem, 
trimethoprim, and thioridazine are eventually introduced 
into tuberculosis treatment regimens.80–86 Linezolid and 
clofazimine are increasingly used for MDR and XDR 
tuberculosis. 
The mechanisms to ensure new tuberculosis drugs are 
preserved for MDR treatment need to be considered in 
view of the need to assess all new drugs for use in 
shortening of drug-sensitive tuberculosis treat ment. 
Parallel approaches are needed to implement regimen 
change in a way that takes into account both the short-
term priority to improve treatment of drug-resistant 
tuberculosis for patients in need today, and the longer-
term goal to develop and test the best regimen 
combinations for patients with drug-susceptible and 
For the STREAM trial see http://
www.controlled-trials.com/
ISRCTN78372190/STREAM
For the TB Alliance trials see 
http://www.tballiance.org/
For the MARVEL study see 
http://www.resisttb.org
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drug-resistant tuberculosis. Novel approaches and 
partnerships are needed to assess new drugs as part of 
regimens for drug-resistant tuberculosis. Examples of 
new partnerships include collaborations between the US 
CDC, the NIH, and the Bill & Melinda Gates Foundation, 
coordination of activities between the US and European 
clinical trials networks, and the support by the Bill & 
Melinda Gates Foundation for the Critical Path to TB 
Drug Regimens.87 Until now, the resources needed to 
adequately treat patients with MDR and XDR tuberculosis 
have been inadequate, and have been dealt with as 
secondary to the broader goals of global tuberculosis 
control. With fewer than one in ﬁ ve patients with MDR 
tuberculosis being treated with second-line drugs,2 and 
only around half of these patients achieving treatment 
success, the need for new treatment approaches has 
never been greater. 
New and repurposed drugs need to be delivered 
through programmatic management of drug-resistant 
tuberculosis.66 Treatment success is substantially 
compromised because of toxicity and complexity,88,89 
which leads to high rates of treatment discontinuation. 
Data from a recent systematic review72 suggest that 
several pro grammatic factors signiﬁ cantly predict low 
default levels, including the use of standardised regimens 
and the ﬂ exible provision of treatment support and 
observation. The treatment of patients in small cohorts 
was also associated with improved adherence, 
presumably because programmes could devote more 
individualised care and support to patients.72 These 
ﬁ ndings show the increased importance of integrated 
and well functioning control programmes to prevent the 
formation and limit the transmission of drug-resistant 
tuberculosis. Therefore, programme scale-up should be 
accompanied by planning and provision of adequate 
resources to ensure successful implementation. 
Adverse events cause patients to default from treatments, 
and underscore the concern that the ability of patients to 
tolerate prescribed treatment regimens, and maintain the 
entire treatment course, is of fundamental importance to 
overall treatment success.90 Shortening of treatment 
duration for drug-resistant tuberculosis is likely to reduce 
default, improve adherence, and beneﬁ t scale-up of 
treatment in many high-burden settings. A new regimen, 
which includes new drugs, but excludes some backbone 
drugs because of tolerability issues, could cure most 
patients with much shorter durations, albeit risking 
relapse in a small percentage of patients.80–86 To eﬀ ectively 
address these various needs will probably need the 
availability of several eﬀ ective agents with low toxicity and 
quality assured use of the new drugs for drug-sensitive and 
drug-resistant tuberculosis in well resourced programmes.
Along with scale-up, simple diagnostic methods to 
detect drug-resistant tuberculosis are needed to ensure 
that patients are not put on failing drug regimens, or on 
regimens in which only one of the drugs in the 
combination is eﬀ ective, resulting in functional 
monotherapy and the acquisition of additional resistance 
or ampliﬁ cation. This need for simple diagnostic 
laboratory methods is particularly important with the 
introduction of new compounds. Responsible access 
programmes with broad national and international 
acceptance should be rapidly designed to protect new 
drugs from inappropriate use that would quickly lead to 
the emergence of resistant strains.80,91 
Improved implementation
Many expert groups and WHO reports66,92,93 have drawn 
attention to major issues in ﬁ nancing of tuberculosis 
control eﬀ orts, universal health coverage, the 
engagement of all care providers including private-for-
proﬁ t practitioners, optimisation of disease manage-
ment and care, improvement of laboratory capacity, 
ensuring of access to quality assured drugs, restriction 
of drug availability, and adequate infection control.94–96 
Many calls for action have not been heeded, despite 
evidence for an increase in MDR and XDR tuberculosis. 
The plans by European governments to address MDR 
tuberculosis18,97 need to be accompanied by sustained 
implementation of these eﬀ orts among all involved. 
Thoughtful political decision making and investment 
of government resources on the basis of expert advice 
and scientiﬁ c evidence is more likely to have lasting 
eﬀ ects on the growing problem of drug-resistant 
tuberculosis than sporadic bursts of focused 
investments in response to predictable outbreaks of 
MDR tuberculosis.
Panel: Recommendations 
• International and national policymakers should ensure that the global funding shortfall 
to support tuberculosis control is urgently met
• The plan to scale up rapid diagnostics to detect tuberculosis, multidrug-resistant, and 
extensively drug-resistant tuberculosis should be accelerated, and be accompanied by 
relevant training and support to ensure appropriate management of patients
• Eﬀ ective infection control practices in health-care facilities should be implemented, and 
opportunities to reduce transmission risk within high-burden communities should be 
explored
• Quality assured second-line drugs for treatment using the WHO recommended regimen 
should be available worldwide, and should be accompanied by a clear plan for the 
rationale use of existing and new drugs
• National programmes should investigate wider social determinants of drug-resistant 
tuberculosis, and establish locally tailored solutions including direct observation of 
treatment, socioeconomic support, and a patient-centred approach to care
• Research activity should increase to ensure the development of new drugs and 
innovative approaches to clinical trials, accurate and cheap diagnostics for ﬁ rst-line and 
second-line drug resistance, and an eﬀ ective vaccine against tuberculosis
• Global policy formulation and investment priorities should be focused on 
evidence-based approaches including those that tackle health-system failures; adequate 
support mechanisms for national programmes to implement WHO recommendations 
should be made available
• All countries should have quality assured surveillance, as recommended by the WHO 
Global Task Force on TB Impact Measurement, to inform control measures
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The ineﬀ ectiveness of national diagnostic, treatment, and 
surveillance eﬀ orts has allowed the continued transmission 
of MDR tuberculosis, and the emergence of XDR 
tuberculosis. To prevent further cases of MDR and XDR 
tuberculosis, a radical change in political and scientiﬁ c 
thinking, and the implementation of speciﬁ c measures 
worldwide are needed (panel). The global economic crisis 
and reduced investments in health services threaten 
national tuberculosis programmes and the gains made in 
global tuberculosis control. The world needs to acknowledge 
the serious threat of drug-resistant tuberculosis, before it 
overwhelms health systems, as is being seen in several 
countries of the former Soviet Union.19
Conclusions
Major conceptual change and visionary global leadership 
are needed to move away from the conventional view that 
tuberculosis is only a disease of poor nations. United and 
motivated advocacy from tuberculosis care, control, 
research, and community participants  is needed to raise 
aware ness that the increase of MDR tuberculosis is a real 
and present danger for the  developed nations and should 
be addressed now with eﬀ ective planning and resource 
allocation. We need to learn from recent examples: drug-
resistant tuberculosis will not subside until the problem is 
controlled globally.72,97,98 Wealthy nations cannot ignore the 
worrying rise of MDR and XDR tuberculosis. 
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